Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page

Q3-2021 Ophthalmology Update

Skip to the end of the Expertise Menu

Q3-2021 Ophthalmology Update

The ophthalmology sector continues to see robust transaction volume and has shown no signs of slowing down. Consolidators that are in the latter stages of their respective hold periods, many of which are exploring a sale themselves, have been particularly aggressive from an acquisition standpoint. Provident expects the next wave of investment and consolidation activity to be characterized by secondary deals in which private equity firms exit their positions in their respective platforms to larger private equity firms with a thesis in the space or larger PE-backed MSOs that are in the earlier stages of their hold period.

Provident represented three premier practices through transactions in the quarter that resulted in excellent outcomes and like-minded partnerships between organizations. We continue to track developments in the space and expect deal volume to keep pace with prior quarters in 2021 and beyond.

To print and download the full Ophthalmology Update┬áreport, please click below…

[holo_button icon=”/wp-content/uploads/2021/10/Q3-2021-Opthalmology-Newsletter.pdf” link=”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]


Sources: SEC Filings; Company Press Releases, and Reports; IBISWorld; Capital IQ; PHP Estimates and Research. This document has been compiled with publicly available information. Provident Healthcare Partners, LLC makes no guarantee of its accuracy or completeness. No data or statement should be construed to be a recommendation for the purchase, sale, or retention of any security.